Barzolvolimab ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 98 | 好酸球性消化管疾患 | 1 |
98. 好酸球性消化管疾患
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05774184 (ClinicalTrials.gov) | May 2023 | 7/3/2023 | A Phase 2 Study of Barzolvolimab in Patients With Eosinophilic Esophagitis | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The EvolvE Study) | Eosinophilic Esophagitis | Biological: barzolvolimab;Drug: Matching Placebo | Celldex Therapeutics | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | NULL |